文献速递腹部介入CTMR

多极双极射频消融治疗肝细胞癌后胆管改变的发生率及临床影响

Incidence and clinical impact of bile ducts changes after multibipolar radiofrequency ablation for hepatocellular carcinoma.
PubMed 文献 · Eur Radiol · 2024-02-09

回顾性纳入2007至2014年连续231例肝硬化患者(266次多极双极射频消融,治疗≤5 cm单结节肝细胞癌),33%出现胆管改变(上游胆管扩张和/或胆汁瘤),平均出现时间3个月。肿瘤浸润性表现和位于VIII段是危险因素;胆管改变组6个月胆红素平均升高更明显(+2.9 vs +0.4 µg/mL,p=0.03),但两组并发症、1年肝硬化失代偿、肿瘤进展及总生存无显著差异。

要点

  • 多极双极射频消融治疗肝细胞癌后33%出现胆管改变(上游胆管扩张和/或胆汁瘤),平均3个月出现。
  • 肿瘤浸润性表现(p=0.035)和位于VIII段(p<0.01)是胆管改变的危险因素。
  • 胆管改变组6个月胆红素平均升高更明显(+2.9 vs +0.4 µg/mL,p=0.03),但1年肝硬化失代偿和总生存无显著差异。

核心结论

  • 多极双极射频消融治疗肝细胞癌后胆管改变常见,尤其见于肿瘤呈浸润性表现或位于VIII段者;这些改变似乎不负面影响1年肝硬化病程或总生存。

研究设计与样本

  • 回顾性收集2007至2014年连续肝硬化患者,均因单结节肝细胞癌(≤5 cm)接受一线多极双极射频消融;共231例患者(平均年龄68岁[39-85],男187例)行266次消融,平均肿瘤大小26 mm;复查影像识别胆管改变,多变量分析评估相关因素。

关键影像表现/征象

  • 胆管改变表现为上游胆管扩张和/或胆汁瘤,76例(33%)出现,平均出现时间3个月。
  • 肿瘤浸润性表现(p=0.035)和位于VIII段(p<0.01)与胆管改变相关。

临床应用与阅片要点

  • 胆管改变组6个月胆红素平均升高+2.9 µg/mL,无胆管改变组+0.4 µg/mL(p=0.03)。
  • 两组并发症、1年肝硬化失代偿(p=0.95)、局部和远处肿瘤进展(p=0.91和0.14)及总生存(p=0.4)无显著差异。
  • 作者认为这些胆管改变不令人担忧,不需要特定监测或干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to evaluate the incidence and clinical implications of bile duct changes following multibipolar radiofrequency ablation (mbpRFA) for hepatocellular carcinoma (HCC).

MATERIALS AND METHODS: Radiological, clinical, and biological data from consecutive cirrhotic patients who underwent first-line mbpRFA between 2007 and 2014 for uninodular HCC ≤ 5 cm were retrospectively collected. Follow-up imaging was reviewed to identify bile duct changes and factors associated with biliary changes were assessed using multivariable analysis. Baseline and 6-month liver function tests were compared in patients with and without bile duct changes. Complications, cirrhosis decompensation, and survival rates were compared in both groups.

RESULTS: A total of 231 patients (mean age 68 years [39-85], 187 men) underwent 266 mbpRFA sessions for uninodular HCC (mean size 26 mm). Of these, 76 (33%) developed bile duct changes (upstream bile duct dilatations and/or bilomas) with a mean onset time of 3 months. Identified risk factors for these changes were the infiltrative aspect of the tumor (p = 0.035) and its location in segment VIII (p < 0.01). The average increase in bilirubin at 6 months was higher in the group with biliary changes (+2.9 vs. +0.4 µg/mL; p = 0.03). There were no significant differences in terms of complications, cirrhosis decompensation at 1 year (p = 0.95), local and distant tumor progression (p = 0.91 and 0.14 respectively), and overall survival (p = 0.4) between the two groups.

CONCLUSION: Bile duct changes are common after mbpRFA for HCC, especially in tumors with an infiltrative aspect or those located in segment VIII. These changes do not appear to negatively impact the course of cirrhosis at 1 year or overall survival.

CLINICAL RELEVANCE STATEMENT: Bile duct changes following mbpRFA for HCC are relatively common. Nevertheless, they do not raise clinical concerns in terms of complications, deterioration in liver function, or survival rates. Consequently, specific monitoring or interventions for these bile duct changes are not warranted.

KEY POINTS: • Bile duct changes are frequently observed after multibipolar radiofrequency ablation for hepatocellular carcinoma, occurring in 33% of cases in our study. • Patients with bile duct changes exhibited a higher increase in bilirubin levels at 6 months but no more cirrhosis decompensation or liver abscesses. • Biliary changes following multibipolar radiofrequency ablation for hepatocellular carcinoma are not alarming and do not necessitate any specific monitoring or intervention.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Varin E, Beunon P, N'Kontchou G, et al. Incidence and clinical impact of bile ducts changes after multibipolar radiofrequency ablation for hepatocellular carcinoma. Eur Radiol. 2024. PMID: 38334763. doi:10.1007/s00330-024-10617-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。